D&O Ongoing Disclosure – David William Kerr

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Ryman Healthcare Limited
Date this disclosure made:25 May 2021
Date of last disclosure: 18 June 2020
Director or senior manager giving disclosure
Full name(s):David William Kerr
Name of listed issuer:Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
(1)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder (together with
Deborah Jane Floyd Kerr) as trustees of
the DW Kerr Family Trust No.2, of which
David Kerr is a beneficiary
For that relevant interest-
Number held in class before acquisition or disposal:358,000
Number held in class after acquisition or disposal:Nil
Current registered holder(s):
David William Kerr and Deborah Jane
Floyd Kerr (as trustees of the DW Kerr
Family Trust No.2)
Registered holder(s) once transfers are registered:
David William Kerr and Deborah Jane
Floyd Kerr
(2)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
(together with Deborah Jane Floyd Kerr)
For that relevant interest-
Number held in class before acquisition or disposal:
Nil
Number held in class after acquisition or disposal:
365,000
Current registered holder(s):
N/A
Registered holder(s) once transfers are registered:
David William Kerr and Deborah Jane
Floyd Kerr
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):

The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Summary of other relevant interests after acquisition or disposal:
Total number of transactions to which notice relates:
Two
Details of transactions requiring disclosure-
(1)
Date of transaction:
25 May 2021
Nature of transaction:
Off market transfer
Name of any other party or parties to the transaction (if known):
David William Kerr and Deborah Jane
Floyd Kerr
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
N/A
Number of financial products to which the transaction related:
358,000
(2)
Date of transaction:
21 May 2021
Nature of transaction:
On market purchase
Name of any other party or parties to the transaction (if known):
N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$97,896.18 (being $13.9852 per share)
Number of financial products to which the transaction related:
7,000
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Other legal holding
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
25 May 2021
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.